BioLineRx Ltd. BLRX Stock
BioLineRx Ltd. Price Chart
BioLineRx Ltd. BLRX Financial and Trading Overview
| BioLineRx Ltd. stock price | 3.28 USD |
| Previous Close | 3.78 USD |
| Open | 3.77 USD |
| Bid | 2.2 USD x 100 |
| Ask | 2.31 USD x 100 |
| Day's Range | 3.44 - 3.77 USD |
| 52 Week Range | 2.15 - 6.59 USD |
| Volume | 50.72K USD |
| Avg. Volume | 48.91K USD |
| Market Cap | 15.66M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.5 USD |
BLRX Valuation Measures
| Enterprise Value | 9.25B USD |
| Trailing P/E | |
| Forward P/E | -5.19403 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 11.168295 |
| Price/Book (mrq) | 0.9666667 |
| Enterprise Value/Revenue | 6600.196 |
| Enterprise Value/EBITDA | -860.788 |
Trading Information
BioLineRx Ltd. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -17.53% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 6.59 USD |
| 52 Week Low | 2.15 USD |
| 50-Day Moving Average | 2.68 USD |
| 200-Day Moving Average | 3.16 USD |
BLRX Share Statistics
| Avg. Volume (3 month) | 48.91K USD |
| Avg. Daily Volume (10-Days) | 204.87K USD |
| Shares Outstanding | 4.35M |
| Float | 2.55B |
| Short Ratio | 5.48 |
| % Held by Insiders | 3.98% |
| % Held by Institutions | 0.44% |
| Shares Short | 139.48K |
| Short % of Float | 3.20% |
| Short % of Shares Outstanding | 3.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -629.76% |
| Gross Margin | 79.24% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.55% |
| Return on Equity (ttm) | -46.72% |
Income Statement
| Revenue (ttm) | 1.4M USD |
| Revenue Per Share (ttm) | 0.6 USD |
| Quarterly Revenue Growth (yoy) | 87.09% |
| Gross Profit (ttm) | 1.11M USD |
| EBITDA | -10750000 USD |
| Net Income Avi to Common (ttm) | -7903000 USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.35M USD |
| Total Cash Per Share (mrq) | 0.007 USD |
| Total Debt (mrq) | 9.07M USD |
| Total Debt/Equity (mrq) | 43.53 USD |
| Current Ratio (mrq) | 1.584 |
| Book Value Per Share (mrq) | 3.6 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7763000 USD |
| Levered Free Cash Flow (ttm) | -5374125 USD |
Profile of BioLineRx Ltd.
| Country | United States |
| State | N/A |
| City | Hevel Modi'in |
| Address | Modi’in Technology Park |
| ZIP | 7177871 |
| Phone | 972 8 642 9100 |
| Website | https://www.biolinerx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 20 |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Q&A For BioLineRx Ltd. Stock
What is a current BLRX stock price?
BioLineRx Ltd. BLRX stock price today per share is 3.28 USD.
How to purchase BioLineRx Ltd. stock?
You can buy BLRX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioLineRx Ltd.?
The stock symbol or ticker of BioLineRx Ltd. is BLRX.
Which industry does the BioLineRx Ltd. company belong to?
The BioLineRx Ltd. industry is Biotechnology.
How many shares does BioLineRx Ltd. have in circulation?
The max supply of BioLineRx Ltd. shares is 4.5M.
What is BioLineRx Ltd. Price to Earnings Ratio (PE Ratio)?
BioLineRx Ltd. PE Ratio is now.
What was BioLineRx Ltd. earnings per share over the trailing 12 months (TTM)?
BioLineRx Ltd. EPS is 0 USD over the trailing 12 months.
Which sector does the BioLineRx Ltd. company belong to?
The BioLineRx Ltd. sector is Healthcare.
BioLineRx Ltd. BLRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}